Trials / Completed
CompletedNCT01774825
IQP-CL-101 in IBS Management
Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- InQpharm Group · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
After 2 weeks of run-in period, subjects are randomized to either IQP-CL-101 or a matching placebo. Over 8 weeks, the subjects are monitored for improvements in IBS symptoms
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | IQP-CL-101 | 2 softgels twice a day |
| OTHER | Placebo | 2 softgels twice a day |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2013-01-24
- Last updated
- 2015-03-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01774825. Inclusion in this directory is not an endorsement.